Stryker Corporation vs Western Alliance Bancorporation — how do they compare? Stryker Corporation trades at $276.39 (market cap $105.64B), while Western Alliance Bancorporation trades at $76.21 (market cap $8.11B). The key difference: Stryker Corporation is far larger — about 13× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays the higher dividend (2.26%). Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 20 Days and Western Alliance Bancorporation for 3 Days on average.
| SYK | WAL | |
|---|---|---|
Market Cap | $105.64B | $8.11B |
Volume | 1,918,844 | 1,479,953 |
Sector | Health | Financials |
52-Week High | $388.35 | $96.08 |
52-Week Low | $269.75 | $66.70 |
Typical Hold Time | 20 Days | 3 Days |
Enterprise Value | $117.10B | $9.63B |
Dividend Yield | 1.28% | 2.26% |
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $275.4, down 1.11% amid a bearish technical signal and negative news flow. The company maintains strong profitability with a 14.43% net margin and a 71% analyst buy rating, but faces headwinds from a manufacturing issue disclosure that triggered an 8.8% stock drop on September 8, 2026. Q3 2026 earnings are due October 29, 2026, following a mixed earnings history with a recent miss in Q1 2026.
The stock presents a divergence between solid fundamentals and near-term sentiment risks. The consensus price target of $368.11 implies significant upside, but ongoing legal investigations and operational challenges pose risks to investor confidence. Earnings growth and resolution of manufacturing issues are critical for sustained recovery.
Western Alliance Bancorporation (WAL) trades at $74.35, down 2.29% on the day, with a bearish technical outlook despite strong fundamentals. The company maintains robust profitability with 25.43% net income margin and 13.43% ROE, supported by recent earnings beats in Q4 2025 and Q1 2026. Recent developments include the launch of WA VenueX digital asset platform and participation in major financial conferences, while institutional investors show mixed positioning.
WAL presents a compelling value opportunity with attractive valuation multiples (P/E 8.39, P/B 1.07) and strong analyst support (79% buy ratings, $84.33 consensus target). However, near-term risks include the recent Q2 2026 EPS miss, bearish technical indicators, and regulatory uncertainty around Fed policy changes affecting bank asset thresholds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →